Information Provided By:
Fly News Breaks for November 13, 2015
WBA, RAD
Nov 13, 2015 | 09:08 EDT
JPMorgan downgraded Rite Aid (RAD) to Neutral with a $9 price target to reflect the pending takeover by Walgreens Boots Alliance (WBA).
News For RAD;WBA From the Last 2 Days
WBA
Mar 28, 2024 | 07:12 EDT
Consensus $3.24. The company said the change reflects challenging retail environment in the U.S., early wind-down of sale-leaseback program, and lower earnings due to Cencora share sales, offset by execution in pharmacy services and a lower adjusted effective tax rate. The company is also maintaining its U.S. Healthcare adjusted EBITDA view to be breakeven at the midpoint of the guidance range of loss of $50M to gain of $50M.
WBA
Mar 28, 2024 | 07:05 EDT
Reports Q2 revenue $37.05B, consensus $35.86B. The company said, "We're encouraged by our first quarter of U.S. Healthcare positive adjusted EBITDA and continued topline growth alongside another quarter of strong execution in pharmacy, as we look to re-energize and evolve its impact both at Walgreens and at large. As we continue to operate in a challenging retail environment, we are taking actions to focus on customer engagement and value.We remain confident in our goal of achieving $1 billion in cost savings this year. We are continuing to strategically review our portfolio over the next three months in an effort to ensure it drives growth and delivers value. Our team members, led by WBA's new executive committee with a track record of operational excellence, are powering our progress as we map growth opportunities, aim to create long-term value across our businesses and execute the hard work to simplify and strengthen WBA."
WBA
Mar 27, 2024 | 13:20 EDT
Notable companies reporting before tomorrow's open, with earnings consensus, include Walgreens Boots Alliance (WBA), consensus 82c.
WBA
Mar 26, 2024 | 06:33 EDT
Morgan Stanley lowered the firm's price target on Walgreens Boots Alliance to $21 from $22 and keeps an Underweight rating on the shares. Ahead of the company's Q2 report, the firm is tempering its FY24 EPS estimate to $3.24 from $3.35 to reflect a variable consumer backdrop. While "hopeful" about Walgreens' turnaround prospects, cost cutting, and pruning of assets, the firm awaits detail on the new CEO's vision and tells investors it is "still likely too early."